Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WLF’s “DDMAC Watch” Objects To Vitrase Ad Division Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

Including the full risk information in the “brief summary” portion of promotional materials is sufficient, Washington Legal Foundation says.

You may also be interested in...



Vitrase Journal Ad Lacks Risk Information, FDA Says

The violative ad for the spreading agent omits warnings, the Division of Drug Marketing, Advertising & Communications states.

FDA Releases DTC Guidances; "Not The Last Word" On Ads, Commissioner McClellan Says

The agency pledges further review of its guidance on direct-to-consumer advertising. Broadcast ads for drugs and enforcement actions against repeat offenders could see more attention.

India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs

Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel